Nektar Therapeutics Severance Costs
Nektar Therapeutics (NKTR) reported Severance Costs of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2025-03-14
- Nektar Therapeutics severance costs for the quarter ending 2024-12-31 was $0.00.
- Nektar Therapeutics severance costs for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics severance costs for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics severance costs for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics severance costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Nektar Therapeutics severance costs for fiscal 2023 was $7.90M, a 74.44% decline from fiscal 2022.
- Nektar Therapeutics severance costs for fiscal 2022 was $30.90M.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month | Severance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $0.00 derived: sum of 2 quarters · filed 2025-03-14 | $0.00 derived: sum of 3 quarters · filed 2025-03-14 | $0.00 10-K · filed 2025-03-14 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | -$61.00K derived: sum of 4 quarters · filed 2025-03-14 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | -$61.00K derived: sum of 3 quarters · filed 2025-03-14 | $474.00K derived: sum of 4 quarters · filed 2025-03-14 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 | -$61.00K derived: sum of 2 quarters · filed 2025-03-14 | $474.00K derived: sum of 3 quarters · filed 2025-03-14 | $2.42M derived: sum of 4 quarters · filed 2025-03-14 | |
| 2023-12-31 | -$61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $474.00K derived: sum of 2 quarters · filed 2025-03-14 | $2.42M derived: sum of 3 quarters · filed 2025-03-14 | $7.90M 10-K · filed 2025-03-14 | $7.88M 10-K · filed 2024-03-05 |
| 2023-09-30 | $535.00K 10-Q · filed 2024-11-08 | $2.48M derived: sum of 2 quarters · filed 2024-11-08 | $7.96M 10-Q · filed 2024-11-08 | $9.04M derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | $1.94M 10-Q · filed 2024-08-09 | $7.43M 10-Q · filed 2024-08-09 | $8.50M derived: sum of 3 quarters · filed 2024-08-09 | $10.58M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | $5.48M 10-Q · filed 2024-05-10 | $6.56M derived: sum of 2 quarters · filed 2024-05-10 | $8.64M derived: sum of 3 quarters · filed 2024-05-10 | $36.39M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $3.15M derived: sum of 2 quarters · filed 2023-02-28 | $30.90M derived: sum of 3 quarters · filed 2023-02-28 | $30.90M 10-K · filed 2023-02-28 | |
| 2022-09-30 | $2.08M 10-Q · filed 2022-11-04 | $29.83M derived: sum of 2 quarters · filed 2022-11-04 | $29.83M 10-Q · filed 2022-11-04 | ||
| 2022-06-30 | $27.75M 10-Q · filed 2022-08-05 | $27.75M 10-Q · filed 2022-08-05 | |||
| 2022-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |